Topics

Cardiovascular diseases

Clinical phenotype of COVID‐19 vaccine‐associated myocarditis in Victoria, 2021–22: a cross‐sectional study

A threefold or greater increase in troponin level may be a clinically useful predictor of cardiac MRI abnormalities

Julia Smith · Silja Schrader · Hannah Morgan · Priya Shenton · Annette Alafaci · Nicholas Cox · Andrew J Taylor · James Hare · Bryn Jones · Nigel W Crawford · Jim P Buttery · Hazel J Clothier · Daryl R Cheng

Mja2 52557

Management of people after stroke in 383 Victorian general practices, 2014–2018: analysis of linked stroke registry and general practice data

The general practice management of people who have been hospitalised with stroke or TIA could be improved

Muideen T Olaiya · Joosup Kim · Christopher Pearce · Kiran Bam · Dominique A Cadilhac · Nadine E Andrew · Lauren M Sanders · Amanda G Thrift · Mark R Nelson · Seana Gall · Monique F Kilkenny

Notification of acute rheumatic fever and rheumatic heart disease in hospitalised people in the Midwest region of Western Australia, 2012–2022: retrospective administrative data analysis

Clinician awareness of notification requirements and automated technology that facilitates ARF/RHD notifications are needed

Ingrid Stacey · Yolande Knight · Claire MX Ong · Amy Lee · Suresh Karuppannan · Allison Christou · Judith M Katzenellenbogen

Cardiovascular diseases News 25 October 2024 Free

The national Cardiovascular Health Leadership Research Forum: a new data-driven model placing research at the centre of improving patient outcomes.

Each year, more than $14 billion is spent by the federal government on the direct health costs of cardiovascular disease, a leading cause of death and disability in Australia. A perspective in the Medical Journal of Australia discusses developing new models to harness Australia’s immense research resources to drive new strategies that can help patient and economic outcomes. “Australia urgently needs a model that connects governments, health service providers and the research workforce to regularly update data on the burden of disease and essential clinical quality indicators,” the authors state. “There is already a wealth of information available for clinical quality improvement, but these data are often fragmented, lack robust metadata and are unable to be accessed in a systematic and timely manner.” The Cardiovascular Health Leadership Research Forum (CV HLRF) connects the health system with Australia’s researchers. It allows funders to invest in, and our health system to implement, prioritised research areas. “Until now, there has been no mechanism that allows for a fully integrated national conversation on CVD [cardiovascular disease] and stroke between the health system, clinicians, researchers, industry partners, state and federal governments, and data and health economics experts.” “It has the potential to accelerate implementation and drive new preventive and therapeutic strategies and foster a vibrant medical technology ecosystem, thereby, positively affecting patient and economic outcomes,” the authors said. The CVHLRF was established in 2022 and was designed and is hosted by the Australian Cardiovascular Alliance (ACvA) — the nation’s peak body for CVD researchers. “Key elements of the CVHLRF include: endorsement by National Health Chief Executive Forum as a valuable model for connecting health, clinical and research leaders to contemporary cardiovascular health data to identify evidence-based research and implementation priorities;commitment of health leaders from all Commonwealth, state and territory health jurisdictions to at least biannual forum meetings;collaborative approach to identifying research and implementation priorities that are deeply relevant to health system needs for CVD;connection to national cardiovascular research workforce through the ACvA for whole-of-pipeline solutions (eg, fundamental mechanisms, new diagnostic and therapeutic tools, bioengineering, clinical trials, and implementation and policy);building of partnerships with health services and industry and moving towards co-commissioned approaches to prioritised areas;commitment to evaluating the clinical and economic impact of interventions prospectively; andsupport for an evolving national data dashboard of standardised cardiovascular outcomes and clinical quality indicators to identify major gaps and inequities.”Read the perspective published by the MJA here.

Sally Block

National Hypertension Taskforce of Australia: a roadmap to achieve 70% blood pressure control in Australia by 2030

Key actions to be taken by the National Hypertension Taskforce, including a roadmap to help implement identified actions

Aletta E Schutte · Belinda Bennett · Clara K Chow · Geoffrey C Cloud · Kerry Doyle · Zoe Girdis · Jonathan Golledge · Andrew Goodman · Charlotte M Hespe · Meng P Hsu · Sharon James · Garry Jennings · Taskeen Khan · Audrey Lee · Lisa Murphy · Mark R Nelson · Stephen J Nicholls · Natalie Raffoul · Breonny Robson · Anthony Rodgers · Andrea Sanders · Catherine Shang · James E Sharman · Nigel P Stocks · Tim Usherwood · Ruth Webster · Jun Yang · Markus Schlaich

Mja2 52373
Neurology Research 1 July 2024 Open Access

First stroke incidence, causes, treatments, and outcomes for Aboriginal Peoples in South Australia and the Northern Territory: a pilot prospective study

A larger, population-based study of the incidence of stroke in Aboriginal people is both feasible and needed

Angela Dos Santos (Gumbaynggirr, Kwiamble) · Edmund Cheong · Anna H Balabanski · Kendall Goldsmith · Luke Burchill (Yorta Yorta, Dja Dja Wurrung) · James Burrow · Stephen Brady · Ferdous Alam · Mark Parsons · Judith M Katzenellenbogen · Amanda G Thrift · Timothy J Kleinig · Alex Brown (Wadi Wadi)

Factors associated with cardiac implantable electronic device‐related infections, New South Wales, 2016–21: a retrospective cohort study

Recognising specific risk factors for CIED-related infections is needed for informed decisions about procedures and prophylactic measures

Md Shajedur Rahman Shawon · Oluwadamisola T Sotade · Joan Li · Michelle D Hill · Liesl Strachan · Gabrielle Challis · Kate King · Sze‐Yuan Ooi · Louisa Jorm

Mja2 52302

Subscribe to MJA email alerts

No spam, you can unsubscribe anytime you want.

By providing your information, you agree to our Terms of Use and our Privacy Policy.

Thanks for Subscribing! Tell us more

Your email updates will use your name.

Good one! Your updates are coming

Thank you for subscribing to the MJA email alerts. Receive the latest content in your inbox.